Description: This report presents Phase 2 of the 2024 IDEC Study, analyzing individual disability income (IDI) claim recovery and mortality rates from 2006-2014. It expands Phase 1's scope—previously limited to 90-day elimination and To Age 65-70 benefit periods—to include additional elimination and benefit periods, examining variations by diagnosis, occupation class, claim year, and gender.

Description: The Society of Actuaries (SOA) Research Institute revisits COVID-19's impact on future U.S. mortality with insights from a multidisciplinary panel of experts. Discover how new variants and other causes of death may influence future mortality trends.

Description: This Society of Actuaries, working with LIMRA, Oliver Wyman and the American Council of Life Insurers, is releasing a series of pulse surveys aimed at obtaining a quick read on how the COVID-19 pandemic is impacting insurance companies and reinsurers.

Description: The Candidate Connect at the 2024 Health Meeting provides information, inspiration and networking opportunities to actuarial candidates pursuing their ASA.

Description: SOA interview with David Axene

Description: This report investigates how mental health diagnoses and social determinants influence life insurance underwriting and mortality risk.

Description: This report is a study. It discusses the objectives, scope, methodology, and limitations of the study, focusing on how diagnosis affects disability income claim recovery and mortality rates.

Description: Investigate the importance of collaboration with accounting, underwriting, sales, marketing and other professions as an actuary when you attend this webcast. Cross-functional positions can cause unique challenges to arise, like various experts attempting to balance growth and profitability. Discover an opportunity to learn about relevant ASOPs and dive deeper into contemporary examples that highlight specific professionalism issues that can develop.

Description: This Society of Actuaries Research Brief has been constructed to highlight some of the key features of the pandemic and contemplate the risks for the actuarial profession to consider in their work.

Description: Cost Effectiveness of Tumor Genomic Analysis and Immunotherapy